UNSPSC 51383508: Indomethacin sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C19H15ClNO4.Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0IMX38M2GG, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, sodium salt, trihydrate but more generally known as indometacin sodium, which bears US NIH Compound Identifier 156283. Most nations, for tariff and trade purposes, schedule indomethacin sodium under HS 29339990.

As of Q4 2014, INDOMETHACIN SODIUM remains US FDA's Preferred Term for this commodity. Indomethacin sodium bears US NLM identifiers UMLS ID C0982211 and NCI Concept Code C47999. SMILES: CC1C(C2CC(CCC2N1C(=O)C3CCC(CC3)CL)OC)CC(=O)[O-].O.O.O.[NA+].

UNSPSC 51383508 Indomethacin sodium is a Commodity code that, based on recent state and local solicitations, encompasses procurement of generic pharmaceuticals and over-the-counter products by health departments, state agencies, and cooperative purchasing alliances supporting community health and pharmacy benefit programs. State and local governments buying under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing organizations that aggregate demand across participating jurisdictions and their authorized wholesale distributors. The scope of work involves supply of manufactured pharmaceuticals with specific National Drug Codes (NDCs), compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and fulfillment through authorized wholesaler networks with chargeback systems, pricing flexibility across multiple formats (flat price, net price, WAC-minus), and quarterly or routine deliveries to designated health facilities.

Recent activity spans Florida, Texas, and Minnesota-led multistate purchasing. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026; response due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring vendor responsibility for shipping and delivery costs and compliance with E-Verify, workers' compensation, and commercial general liability insurance. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for value-based contracting outside traditional pharmacy benefit manager and group purchasing organization arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026; proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with awards effective July 1, 2026, requiring submission through ePro with pricing weighted at 75 percent of evaluation, compliance with cGMP and DSCSA, and maintenance of contractual relationships with at least two of three authorized wholesalers.